What is Scala Biodesign?
Scala Biodesign operates at the intersection of artificial intelligence and molecular biology, providing a sophisticated computational framework for the design and optimization of proteins. The company's proprietary technology integrates evolutionary data with structural modeling to enhance the stability, activity, and manufacturability of essential biologics, including enzymes and antibodies. By streamlining the traditional, labor-intensive experimental processes, Scala Biodesign enables pharmaceutical and chemical manufacturers to accelerate the development of high-performance bioproducts. This technological edge allows the company to address critical bottlenecks in drug discovery and sustainable industrial manufacturing, effectively reducing the time-to-market for complex biological assets.
How much funding has Scala Biodesign raised?
Scala Biodesign has raised a total of $21.5M across 2 funding rounds:
Angel/Seed
$5.5M
Series A
$16M
Angel/Seed (2023): $5.5M with participation from TLV Partners
Series A (2026): $16M led by Israel Innovation Authority, TLV Partners, Grove Ventures Ltd, and Deep Insight
Key Investors in Scala Biodesign
Israel Innovation Authority
A government-backed entity dedicated to fostering technological innovation in Israel by providing essential funding and support to startups and research-intensive companies.
TLV Partners
An Israeli venture capital firm managing over $1 billion, specializing in early-stage investments across AI, healthcare, and application security sectors.
Grove Ventures Ltd
A leading early-stage investment firm focused on deep tech, partnering with entrepreneurs to build foundational technologies for the future.
What's next for Scala Biodesign?
With the infusion of this latest capital, Scala Biodesign is poised to scale its computational infrastructure and expand its reach within the global pharmaceutical and chemical markets. The strategic focus will likely shift toward deepening its R&D capabilities to tackle more complex protein structures while simultaneously strengthening its commercial partnerships. As the company matures, the integration of its AI-driven platform into large-scale industrial workflows will be a key performance indicator. Investors are closely monitoring how the firm utilizes these resources to maintain its competitive advantage in the rapidly evolving landscape of bio-convergence and deep tech innovation.
See full Scala Biodesign company page
